Company Performance Metrics
Encysive Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes synthetic and small molecule compounds to address medical needs worldwide. The company focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade, and
vascular diseases. Its products include Argatroban for the treatment of heparin-induced thrombocytopenia; and Thelin (sitaxsentan sodium), an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, congestive heart failure, and essential hypertension. The company's clinical development compounds include TBC3711, an endothelin receptor antagonist; TBC4746, an antigen-4 antagonist; ENC8003, a G protein-coupled receptor; and bimosiamose, a selectin antagonist. Encysive Pharmaceuticals has research collaboration and license agreements with GlaxoSmithKline plc; Mitsubishi Pharma Corporation; Schering-Plough, Ltd.; Schering Corporation; and Revotar Biopharmaceuticals, AG. The company was founded in 1989. It was formerly known as Texas Biotechnology Corporation and changed its name to Encysive Pharmaceuticals, Inc. in 2003. Encysive Pharmaceuticals is based in Houston, Texas. As of June 10, 2008, Encysive Pharmaceuticals Inc. operates as a subsidiary of Pfizer Inc.
